文献速递急性肾损伤肾小球疾病遗传性与小管间质肾病

单克隆丙种球蛋白病相关补体激活与血栓性微血管病:法国全国病例系列

Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.
PubMed 文献 · Am J Kidney Dis · 2022-02-22

法国2000至2020年全国HUS登记中24例无其他继发TMA原因的单克隆丙种球蛋白病患者的病例系列显示,该病较成人aHUS约少见10倍,17/24例起病时需透析,中位肾脏生存仅20个月,补体检查提示替代途径和终末途径参与。

要点

  • 单克隆丙种球蛋白病相关TMA较成人aHUS约少见10倍
  • 17/24例起病时需透析,中位肾脏生存仅20个月
  • 补体检查示低C3者33%、C4正常者100%、可溶性C5b-9升高者77%

核心结论

  • 单克隆丙种球蛋白病相关TMA是TMA谱中一个独特亚型,作者认为单克隆免疫球蛋白相关HUS是类似aHUS的补体介导疾病。

研究设计与样本

  • 法国全国HUS登记中2000至2020年的病例系列,纳入24例无其他继发TMA原因的单克隆丙种球蛋白病患者。

主要发现

  • 单克隆丙种球蛋白病相关TMA伴肾脏受累的估计频率较法国全国登记中成人aHUS低10倍。
  • 24例中17例起病时需要透析,中位肾脏生存仅20个月。
  • TMA介导的肾外表现常见,尤其皮肤和神经系统受累,并与总体预后差相关。
  • 补体检查在受检患者中分别有33%低C3、100%C4正常、77%可溶性C5b-9升高,提示替代途径和终末补体途径参与疾病病理生理。
  • 在17例接受检测者中仅3例(17%)发现与aHUS相关的补体基因异常。

局限性

  • 回顾性研究,无对照组。
  • 患者数量有限。
  • 可获得的血液样本有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Hemolytic uremic syndrome (HUS), a thrombotic microangiopathy (TMA) with kidney involvement, is a rare condition in patients with monoclonal gammopathy. In the absence of known causes of TMA, the role of complement activation in endothelial injury in patients with monoclonal gammopathy remains unknown and was the focus of this investigation. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: We studied the 24 patients in the French national registry of HUS between 2000 and 2020 who had monoclonal gammopathy without other causes of secondary TMA. We provide the clinical histories and complement studies of these patients. FINDINGS: Monoclonal gammopathy-associated TMA with kidney involvement is estimated to be 10 times less frequent than adult atypical HUS (aHUS) in the French national registry. It is characterized by severe clinical features, with 17 of 24 patients requiring dialysis at disease onset, and with median renal survival of only 20 months. TMA-mediated extrarenal manifestations, particularly cutaneous and neurological involvement, were common and associated with poor overall prognosis. Complement studies identified low C3, normal C4, and high soluble C5b-9 levels in 33%, 100%, and 77% of tested patients, respectively, indicating a contribution of the alternative and terminal complement pathways in the pathophysiology of the disease. Genetic abnormalities in complement genes known to be associated with aHUS were found in only 3 of 17 (17%) who were tested. LIMITATIONS: Retrospective study without comparison group; limited number of patients, limited available blood samples. CONCLUSIONS: Within the spectrum of TMA, TMA associated with monoclonal gammopathy represents a distinct subset. Our findings suggest that HUS associated with monoclonal immunoglobulin is a complement-mediated disease akin to aHUS.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Martins M, Bridoux F, Goujon JM, et al. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series. Am J Kidney Dis. 2022. PMID: 35217094. doi:10.1053/j.ajkd.2021.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。